An editorial by Robert Howard and Helen Kales in BMJ (2023;382:p1852) addresses new treatments for Alzheimer's disease. The statement of competing interests has been amended. Robert Howard is an unpaid member of the Synaptogenix Scientific Advisory Board. These facts represent the only verified information from the provided content of the article.[1]